ACADIA Pharmaceuticals Overview
- Founded
-
1993
- Status
-
Public
- Employees
-
500
- Stock Symbol
-
ACAD
- Investments
-
1
- Share Price
-
$16.96
- (As of Tuesday Closing)
ACADIA Pharmaceuticals General Information
Description
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 12830 El Camino Real
- Suite 400
- San Diego, CA 92130
- United States
+1 (858) 000-0000
ACADIA Pharmaceuticals Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.96 | $16.60 | $12.24 - $28.05 | $2.69B | 162M | 2.7M | -$1.27 |
ACADIA Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 1,892,985 | 3,277,580 | 7,903,728 | 5,915,630 |
| Revenue | 512,401 | 484,145 | 441,755 | 339,076 |
| EBITDA | (202,225) | (164,766) | (284,651) | (242,782) |
| Net Income | (204,618) | (167,870) | (281,584) | (235,259) |
| Total Assets | 612,766 | 700,122 | 782,616 | 783,183 |
| Total Debt | 63,717 | 64,430 | 49,547 | 9,795 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ACADIA Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ACADIA Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address
Pharmaceuticals
San Diego, CA
500
As of 2022
00000
000000&0
0000 0
liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000000000000
Cambridge, MA
000
As of 0000
00.000
000000000
00.000
00 000
fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia de
0000000000000
Paris, France
00
As of 0000
000.00
000000000
000.00
Add Comparison
ACADIA Pharmaceuticals Competitors (60)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| 00 0000000 | Formerly Accelerator/Incubator backed | Paris, France | 00 | 000.00 | 000000000 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
| 00000000 000000000 | Formerly VC-backed | Switzerland | 00 | 00000 | 000000000 | 00000 |
| 00000000 | Venture Capital-Backed | New Haven, CT | 00 | 00000 | 00000000 | 00000 |
ACADIA Pharmaceuticals Patents
ACADIA Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210161880-A1 | Methods for treating dementia related psychosis | Pending | 02-Dec-2019 | 0000000000 | |
| US-20200289474-A1 | Methods of treating pain with a thiazoline anti-hyperalgesic | Abandoned | 01-Feb-2019 | 0000000000 | |
| US-20220168279-A1 | Methods of treating pain with a thiazoline anti-hyperalgesic | Pending | 01-Feb-2019 | 0000000000 | |
| US-20200246316-A1 | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent | Abandoned | 01-Feb-2019 | 0000000000 | 0 |
| US-20200246318-A1 | Methods of treating pain with a thiazoline anti-hyperalgesic | Abandoned | 01-Feb-2019 | A61K31/426 |
ACADIA Pharmaceuticals Executive Team (26)
ACADIA Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Daniel Soland | Self | Board Member | 000 0000 |
| Edmund Harrigan MD | Self | Board Member | 000 0000 |
| Elizabeth Garofalo MD | Self | Board Member | 000 0000 |
| Julian Baker | Self | Board Member | 000 0000 |
| Laura Brege | ACADIA Pharmaceuticals | Board Member | 000 0000 |
ACADIA Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ACADIA Pharmaceuticals Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 01-Aug-2020 | 0000000000 | 000.00 | Biotechnology | 0000000 0 |
ACADIA Pharmaceuticals Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000 (000000000000 | Biotechnology | Skokie, IL | 0000 |